Life Cycle Investment Partners Ltd Makes New Investment in Bristol Myers Squibb Company $BMY

Life Cycle Investment Partners Ltd acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 637,858 shares of the biopharmaceutical company’s stock, valued at approximately $34,406,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. EverSource Wealth Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 218.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 28,857 shares of the biopharmaceutical company’s stock worth $1,557,000 after buying an additional 19,794 shares during the last quarter. New Millennium Group LLC grew its holdings in shares of Bristol Myers Squibb by 7,200.0% during the fourth quarter. New Millennium Group LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 3,240 shares during the last quarter. Delta Financial Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 10.2% during the fourth quarter. Delta Financial Advisors LLC now owns 26,026 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 2,414 shares during the last quarter. Americana Partners LLC grew its holdings in shares of Bristol Myers Squibb by 1.7% during the fourth quarter. Americana Partners LLC now owns 211,328 shares of the biopharmaceutical company’s stock worth $11,399,000 after buying an additional 3,443 shares during the last quarter. Finally, Legato Capital Management LLC grew its holdings in shares of Bristol Myers Squibb by 136.3% during the fourth quarter. Legato Capital Management LLC now owns 99,584 shares of the biopharmaceutical company’s stock worth $5,372,000 after buying an additional 57,438 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Transactions at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $59.51 on Friday. The business’s 50 day simple moving average is $58.46 and its 200-day simple moving average is $55.86. The firm has a market capitalization of $121.51 billion, a price-to-earnings ratio of 16.71, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.80 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.31 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Royal Bank Of Canada started coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. HSBC lifted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a report on Tuesday, March 17th. Bank of America lowered their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a report on Thursday, April 9th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Sunday, April 19th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.